NEW YORK (GenomeWeb) – BC Platforms is joining with with medical evidence provider Medaffcon in an effort to harmonize genomic and clinical data gathered from multiple sources, the companies said today. Financial terms of the partnership were not disclosed.
Medaffcon specializes in generating medical evidence from biobank-based research. Under the partnership with Switzerland-based BC Platforms, Medaffcon will be leveraging the BCRquest.com global biobank analytics platform, the companies said.
"The collaboration will expand our capabilities of accessing and combining different Finnish and international data sources to advance research," Jaana Ahlamaa, Medaffcon's medical and market access director, said in a statement.
"Our goal is to combine our global platform to leverage Medaffcon's extensive expertise in key markets in order to utilize real-world evidence faster and more effectively," added BC Platforms CEO Tero Silvola.
Espoo, Finland-based Medaffcon is a wholly owned subsidiary of German pharmaceutical distributor the Phoenix Group.